EUVIMEDEUVIMED entdecken
Crossref

Emerging Role of Liquid Chromatography–Mass Spectrometry in the Clinical Laboratory Evaluation of Chronic Autonomic Failure

David S Goldstein iD, Patti Sullivan, Courtney Holmes, Ido Kema, Martijn van Faassen

Journal of Neurochemistry · 2026-03 · 170 (3)

DOI: 10.1111/jnc.70405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 12.03.2026. Verfasst von David S Goldstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Heal…. Hauptthemen laut MEDLINE: Liquid Chromatography-Mass Spectrometry, Pure Autonomic Failure. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Institute of Neurological Disorders and Stroke, Division of Intramural Research, NIH HHS, U.S. Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid chromatography with electrochemical detection (LC‐ED) after batch alumina extraction has been the mainstay for assaying levels of catecholamines and related 3,4‐dihydroxy compounds (catechols) as part of the clinical laboratory workup of patients with neurogenic orthostatic hypotension, especially in the setting of the autonomic synucleinopathies Parkinson disease with orthostatic hypotension (PD + OH), pure autonomic failure (PAF), and multiple system atrophy (MSA). Liquid chromatography with tandem mass spectrometry (LC–MS/MS) is faster and measures catechols and non‐catechol metabolites simultaneously but has not yet been validated sufficiently against LC‐ED or used to assess catechol vs. non‐catechol neurochemical abnormalities in autonomic synucleinopathies. We measured plasma catechols by LC–MS/MS and LC‐ED in patients with PAF, PD + OH, or MSA and healthy controls. Cardiac sympathetic neuroimaging by 18 F‐dopamine positron emission tomography (PET) was used to indicate myocardial norepinephrine (NE) content in the same subjects. Across 41 participants (12 PAF, 9 PD + OH, 10 MSA, 10 controls) individual values for plasma 3,4‐dihydroxyphenylglycol (DHPG), NE, and 3,4‐dihydroxyphenylalanine (DOPA) by LC–MS/MS correlated positively with values by LC‐ED ( r = 0.97, 0.98, and 1.00, p < 0.0001 each). The PAF group had low mean NE, DHPG, normetanephrine, 3‐methoxy‐4‐hydroxyphenylglycol, epinephrine, and metanephrine compared to the PD + OH group, while cardiac PET did not separate the 2 groups. We therefore conclude that LC–MS/MS validly assays plasma catechols. Several catechol and non‐catechol biomarkers of generalized catecholamine deficiency separate PAF from PD + OH but not PD + OH from MSA, while 18 F‐dopamine PET separates PAF and PD + OH from MSA but not PAF from PD + OH. Combining LC–MS/MS with cardiac sympathetic neuroimaging efficiently differentiates among these conditions. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liquid Chromatography-Mass SpectrometryPure Autonomic FailureHumansCatecholsFemaleMiddle AgedMaleMultiple System AtrophyAgedParkinson DiseaseTandem Mass SpectrometryHypotension, OrthostaticPositron-Emission Tomography

Stichwörter der Autor:innen

Parkinsonautonomic failuremass spectrometrymultiple system atrophyorthostatic hypotension

Substanzen

Catechols

Autor:innen und Institutionen

  • Clinical Neurosciences Program, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

ORCID-Profile: David S Goldstein

Förderung

  • National Institute of Neurological Disorders and Stroke, Division of Intramural Research
  • NIH HHS
  • U.S. Department of Health and Human Services
  • National Institute of Neurological Disorders and Stroke
  • National Institutes of Health

Zitieren

APA

Goldstein, D. S., Sullivan, P., Holmes, C., Kema, I., & van Faassen, M. (2026). Emerging Role of Liquid Chromatography–Mass Spectrometry in the Clinical Laboratory Evaluation of Chronic Autonomic Failure. Journal of Neurochemistry, 170(3). https://doi.org/10.1111/jnc.70405

Vancouver

Goldstein DS, Sullivan P, Holmes C, Kema I, van Faassen M. Emerging Role of Liquid Chromatography–Mass Spectrometry in the Clinical Laboratory Evaluation of Chronic Autonomic Failure. Journal of Neurochemistry. 2026;170(3). doi:10.1111/jnc.70405

BibTeX
@article{Goldstein2026,
  author = {Goldstein, David S and Sullivan, Patti and Holmes, Courtney and Kema, Ido and van Faassen, Martijn},
  title = {Emerging Role of Liquid Chromatography–Mass Spectrometry in the Clinical Laboratory Evaluation of Chronic Autonomic Failure},
  journal = {Journal of Neurochemistry},
  year = {2026},
  volume = {170},
  number = {3},
  doi = {10.1111/jnc.70405}
}
Kostenlos starten →